Cargando…
Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis
PURPOSE: Cardiotoxicity affects 5–16% of cancer patients who receive anthracyclines and/or trastuzumab. Limited research has examined interventions to mitigate cardiotoxicity. We examined the role of statins in mitigating cardiotoxicity by performing a systematic review and meta-analysis of publishe...
Autores principales: | Obasi, Mary, Abovich, Arielle, Vo, Jacqueline B., Gao, Yawen, Papatheodorou, Stefania I., Nohria, Anju, Asnani, Aarti, Partridge, Ann H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541988/ https://www.ncbi.nlm.nih.gov/pubmed/34406595 http://dx.doi.org/10.1007/s10552-021-01487-1 |
Ejemplares similares
-
Genetics of Anthracycline-Associated Cardiotoxicity
por: Al-Otaibi, Talal Khalid, et al.
Publicado: (2022) -
Anthracycline Cardiotoxicity: Can CT Move Us Further?
por: Campia, Umberto, et al.
Publicado: (2020) -
Decision Science Can Inform Clinical Trade-Offs Regarding Cardiotoxic Cancer Treatments
por: Gillman, Arielle S, et al.
Publicado: (2021) -
Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers
por: Henninger, Christian, et al.
Publicado: (2017) -
Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab
por: Altomare, Claudia, et al.
Publicado: (2021)